CoChat

Activation of 5-HT2A/C Receptors Counteracts 5-HT1A Regulation of N-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex

Open access
Yuen, Eunice Y., Jiang, Qian, Chen, Paul, Feng, Jian, Yan, Zhen · 2008 · Journal of Biological Chemistry

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Abnormal serotonin-glutamate interaction in prefrontal cortex (PFC) is implicated in the pathophysiology of many mental disorders, including schizophrenia and depression. However, the mechanisms by which this interaction occurs remain unclear. Our previous study has shown that activation of 5-HT(1A) receptors inhibits N-methyl-D-aspartate (NMDA) receptor (NMDAR) currents in PFC pyramidal neurons by disrupting microtubule-based transport of NMDARs. Here we found that activation of 5-HT(2A/C) receptors significantly attenuated the effect of 5-HT(1A) on NMDAR currents and microtubule depolymerization. The counteractive effect of 5-HT(2A/C) on 5-HT(1A) regulation of synaptic NMDAR response was also observed in PFC pyramidal neurons from intact animals treated with various 5-HT-related drugs. Moreover, 5-HT(2A/C) stimulation triggered the activation of extracellular signal-regulated kinase (ERK) in dendritic processes. Inhibition of the beta-arrestin/Src/dynamin signaling blocked 5-HT(2A/C) activation of ERK and the counteractive effect of 5-HT(2A/C) on 5-HT(1A) regulation of NMDAR currents. Immunocytochemical studies showed that 5-HT(2A/C) treatment blocked the inhibitory effect of 5-HT(1A) on surface NR2B clusters on dendrites, which was prevented by cellular knockdown of beta-arrestins. Taken together, our study suggests that serotonin, via 5-HT(1A) and 5-HT(2A/C) receptor activation, regulates NMDAR functions in PFC neurons in a counteractive manner. 5-HT(2A/C), by activating ERK via the beta-arrestin-dependent pathway, opposes the 5-HT(1A) disruption of microtubule stability and NMDAR transport. These findings provide a framework for understanding the complex interactions between serotonin and NMDARs in PFC, which could be important for cognitive and emotional control in which both systems are highly involved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m801713200

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1. Activation of 5-HT2A/C receptors counteracts the 5-HT1A -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons. A and C, plot of normalized peak NMDAR currents (A) or NMDAR-EPSC (C) as a function of time and 8-OH-DPAT (5-HT1A agonist, 20 μm) application in neurons treated with or without α-Me-5HT (5-HT2A/C agonist, 20 μm). Each point (C) represents the average peak (mean ± S.E.) of three consecutive NMDAR-EPSC. B and D, representative current traces taken from the records used to construct A or C (at time points denoted by #). Scale bars: 100 pA, 1 s (B); 100 pA, 100 ms (D). E, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) and ketanserin (5-HT2A/C antagonist, 20 μm). F, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, p < 0.001, ANOVA.
FIGURE 1. Activation of 5-HT2A/C receptors counteracts the 5-HT1A -induced reduction of NMDAR-mediated ionic and synaptic currents in PFC pyramidal neurons. A and C, plot of normalized peak NMDAR currents (A) or NMDAR-EPSC (C) as a function of time and 8-OH-DPAT (5-HT1A agonist, 20 μm) application in neurons treated with or without α-Me-5HT (5-HT2A/C agonist, 20 μm). Each point (C) represents the average peak (mean ± S.E.) of three consecutive NMDAR-EPSC. B and D, representative current traces taken from the records used to construct A or C (at time points denoted by #). Scale bars: 100 pA, 1 s (B); 100 pA, 100 ms (D). E, plot of peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) and ketanserin (5-HT2A/C antagonist, 20 μm). F, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the presence or absence of various 5-HT receptor agonists or antagonists. *, p < 0.001, ANOVA.CC BY-NC · PubMed Central
FIGURE 2. Inhibition of 5-HT2A/C receptors unmasks the 5-HT1A -mediated reduction of NMDAR-EPSC in response to 5-HT. A, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 μm) in neurons treated with or without the 5-HT2A/C antagonist ketanserin (ket, 20 μm). Scale bars: 100 pA, 100 ms. B, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, p < 0.001, ANOVA.
FIGURE 2. Inhibition of 5-HT2A/C receptors unmasks the 5-HT1A -mediated reduction of NMDAR-EPSC in response to 5-HT. A, representative NMDAR-EPSC traces (average of three trials) showing the regulation of NMDAR-EPSC by 5-HT (10, 40, or 100 μm) in neurons treated with or without the 5-HT2A/C antagonist ketanserin (ket, 20 μm). Scale bars: 100 pA, 100 ms. B, dose-response curves summarizing the percentage reduction of NMDAR-EPSC by different concentrations of 5-HT in neurons treated with or without ketanserin. *, p < 0.001, ANOVA.CC BY-NC · PubMed Central
FIGURE 3. The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT1A agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT2A/C agonist. A and B, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. A, saline, 8-OH-DPAT, α-Me-5HT, or 8-OH-DPAT plus α-Me-5HT; B, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by short bars. Inset: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. Scale bars: 100 pA, 100 ms. C, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 μm) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.
FIGURE 3. The synaptic NMDA response is reduced in PFC pyramidal neurons from animals with systemic administration of 5-HT1A agonist or the serotonin re-uptake inhibitor fluoxetine, which is opposed by injecting 5-HT2A/C agonist. A and B, dot plots showing the peak amplitude of NMDAR-EPSC recorded in PFC pyramidal neurons from animals with a single intraperitoneal injection of different drugs. A, saline, 8-OH-DPAT, α-Me-5HT, or 8-OH-DPAT plus α-Me-5HT; B, saline, fluoxetine, WAY-100635, WAY-100635 plus fluoxetine, ketanserin, or ketanserin plus fluoxetine. All drugs were at the concentration of 20 mg/kg. Animals were sacrificed for slicing 1 h after drug administration. Mean values of each group are indicated by short bars. Inset: representative NMDAR-EPSC traces recorded in PFC pyramidal neurons from animals with different drug injection. Scale bars: 100 pA, 100 ms. C, plot of normalized peak NMDAR-EPSC showing the effect of bath application of 8-OH-DPAT (40 μm) in PFC pyramidal neurons from animals intraperitoneally injected with fluoxetine (20 mg/kg) or saline.CC BY-NC · PubMed Central
FIGURE 4. Activation of 5-HT2A/C receptors attenuates the 5-HT1A -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC. A, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40μm, 30 min) in the absence or presence of α-Me-5HT (20 μm, added 10 min before 8-OH-DPAT treatment). B, quantification of free tubulin assay. Free tubulin level was normalized to control (–), based on the intensity of the tubulin band from Western blot analyses. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 μm) in the absence or presence of α-Me-5HT (20 μm). D, cumulative data (mean ± S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to α-Me-5HT. *, p < 0.05, ANOVA.
FIGURE 4. Activation of 5-HT2A/C receptors attenuates the 5-HT1A -induced microtubule depolymerization and the effect of microtubule depolymerizer on NMDAR-EPSC. A, Western blot analysis of free tubulin in lysates of cultured PFC neurons treated with or without 8-OH-DPAT (40μm, 30 min) in the absence or presence of α-Me-5HT (20 μm, added 10 min before 8-OH-DPAT treatment). B, quantification of free tubulin assay. Free tubulin level was normalized to control (–), based on the intensity of the tubulin band from Western blot analyses. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of microtubule depolymerizer colchicine (30 μm) in the absence or presence of α-Me-5HT (20 μm). D, cumulative data (mean ± S.E.) illustrating the percent reduction of NMDAR-EPSC by colchicine in neurons with or without the exposure to α-Me-5HT. *, p < 0.05, ANOVA.CC BY-NC · PubMed Central
FIGURE 5. Activation of 5-HT2A/C receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons. A and B, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (A, green) or ERK (B, green) plus the nucleus marker TOPRO3 (red) in the absence (vehicle) or presence of α-Me-5HT (20 μm, 3 min) or glutamate (100 μm, 3 min).
FIGURE 5. Activation of 5-HT2A/C receptors induces the phosphorylation and activation of ERK in neuronal dendrites in cultured PFC neurons. A and B, immunocytochemical images of cultured PFC neurons stained with phospho-ERK (A, green) or ERK (B, green) plus the nucleus marker TOPRO3 (red) in the absence (vehicle) or presence of α-Me-5HT (20 μm, 3 min) or glutamate (100 μm, 3 min).CC BY-NC · PubMed Central
FIGURE 6. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function is dependent on the β-arrestin/ERK pathway. A, top: Western blots of β-arrestin 1/2 in PFC cultures transfected without or with siRNA against β-arrestin 1/2 or a scrambled siRNA. Quantification of β-arrestin 1/2 expression under different conditions. Each point represents mean ± S.E. of three independent experiments. *, p < 0.001, ANOVA. B, top: Western blots of phospho-ERK in the absence or presence of α-Me-5HT (20 μm, 3 min) in PFC cultures transfected with or without β-arrestin 1/2 siRNA. Bottom: quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20μm) application in the presence ofα-Me-5HT (20 μm) in GFP-positive neurons transfected with or without siRNA against β-arrestin 1/2. D, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence ofα-Me-5HT under different conditions. *, p < 0.001, ANOVA.
FIGURE 6. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function is dependent on the β-arrestin/ERK pathway. A, top: Western blots of β-arrestin 1/2 in PFC cultures transfected without or with siRNA against β-arrestin 1/2 or a scrambled siRNA. Quantification of β-arrestin 1/2 expression under different conditions. Each point represents mean ± S.E. of three independent experiments. *, p < 0.001, ANOVA. B, top: Western blots of phospho-ERK in the absence or presence of α-Me-5HT (20 μm, 3 min) in PFC cultures transfected with or without β-arrestin 1/2 siRNA. Bottom: quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of peak NMDAR currents as a function of time and 8-OH-DPAT (20μm) application in the presence ofα-Me-5HT (20 μm) in GFP-positive neurons transfected with or without siRNA against β-arrestin 1/2. D, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR currents by 8-OH-DPAT in the absence or presence ofα-Me-5HT under different conditions. *, p < 0.001, ANOVA.CC BY-NC · PubMed Central
FIGURE 7. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis. A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without α-Me-5HT (20 μm, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 μm), or a cell-permeable scrambled control peptide (50 μm). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before α-Me-5HT treatment. B, quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) in cells dialyzed with the dynamin inhibitory peptide (50 μm) or a scrambled control peptide (50 μm). Inset, representative traces of NMDAR-EPSC taken at time points denoted by #. Scale bars: 100 pA, 10 ms. D, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of α-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, p < 0.001, ANOVA.
FIGURE 7. The counteractive effect of 5-HT2A/C on 5-HT1A regulation of NMDAR function involves clathrin/dynamin-mediated endocytosis. A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without α-Me-5HT (20 μm, 3 min) in the absence or presence of the cell-permeable (myristoylated) or non-permeable dynamin inhibitory peptide (both 50 μm), or a cell-permeable scrambled control peptide (50 μm). This scrambled peptide was fused with the protein transduction domain of the human immunodeficiency virus TAT protein (YGRKKRRQRRR, 53), which rendered it cell-permeable. All peptides were added 30 min before α-Me-5HT treatment. B, quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) in cells dialyzed with the dynamin inhibitory peptide (50 μm) or a scrambled control peptide (50 μm). Inset, representative traces of NMDAR-EPSC taken at time points denoted by #. Scale bars: 100 pA, 10 ms. D, cumulative data (mean ± S.E.) summarizing the percentage reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of α-Me-5HT in neurons injected with or without the dynamin inhibitory peptide. *, p < 0.001, ANOVA.CC BY-NC · PubMed Central
FIGURE 8. Inhibition of Src prevents 5-HT2A/C from opposing 5-HT1A regulation of NMDAR currents. A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without α-Me-5HT (20 μm, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 μm, added 30 min before α-Me-5HT treatment). B, quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) in cells injected with PP2 (20 μm) or PP3 (20 μm). Inset, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. Scalebars: 100 pA, 100 ms. D, cumulative data (mean ± S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of α-Me-5HT under different conditions. *, p < 0.001, ANOVA.
FIGURE 8. Inhibition of Src prevents 5-HT2A/C from opposing 5-HT1A regulation of NMDAR currents. A, Western blots of phospho-ERK and total ERK in PFC cultures treated with or without α-Me-5HT (20 μm, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 μm, added 30 min before α-Me-5HT treatment). B, quantification of phospho-ERK under different conditions. Each point represents mean ± S.E. of 4–5 independent experiments. *, p < 0.001, ANOVA. C, plot of normalized peak NMDAR-EPSC showing the effect of 8-OH-DPAT (20 μm) in the presence of α-Me-5HT (20 μm) in cells injected with PP2 (20 μm) or PP3 (20 μm). Inset, representative traces of NMDAR-EPSC (average of three trials) taken at time points denoted by #. Scalebars: 100 pA, 100 ms. D, cumulative data (mean ± S.E.) showing the percent reduction of NMDAR-EPSC by 8-OH-DPAT in the absence or presence of α-Me-5HT under different conditions. *, p < 0.001, ANOVA.CC BY-NC · PubMed Central
FIGURE 9. Activation of 5-HT2A/C receptors opposes the 5-HT1A -induced decrease of surface NR2B clusters on neuronal dendrites. A–F, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or withoutβ-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 μm, 5 min) in the absence or presence of α-Me-5HT (20 μm, added 10 min before 8-OH-DPAT treatment). Enlarged versions of the boxed regions of dendrites are shown beneath each of the images. G, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, p < 0.01, ANOVA.
FIGURE 9. Activation of 5-HT2A/C receptors opposes the 5-HT1A -induced decrease of surface NR2B clusters on neuronal dendrites. A–F, immunocytochemical images of surface GFP-NR2B clusters in PFC cultures transfected with or withoutβ-arrestin2 siRNA. Cultures were untreated (control) or treated with 8-OH-DPAT (40 μm, 5 min) in the absence or presence of α-Me-5HT (20 μm, added 10 min before 8-OH-DPAT treatment). Enlarged versions of the boxed regions of dendrites are shown beneath each of the images. G, quantitative analysis of surface GFP-NR2B clusters (cluster density, size, and intensity) along dendrites under different treatments. *, p < 0.01, ANOVA.CC BY-NC · PubMed Central
FIGURE 10. The surface NMDAR level is reduced in PFC from fluoxetine-injected animals. A, Western blot analysis showing the surface and total NR1, NR2B, and GABAAR β2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). B, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, p < 0.01; **, p < 0.001; ANOVA.
FIGURE 10. The surface NMDAR level is reduced in PFC from fluoxetine-injected animals. A, Western blot analysis showing the surface and total NR1, NR2B, and GABAAR β2 subunits in lysates of PFC slices taken from animals receiving a single intraperitoneal injection of saline, fluoxetine, ketanserin, ketanserin plus fluoxetine, WAY-100635, or WAY-100635 plus fluoxetine (all drugs are 20 mg/kg). B, quantification of surface NMDAR subunits in PFC slices from animals treated with different drugs. *, p < 0.01; **, p < 0.001; ANOVA.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Gout, 1993, Cell, 75, 25, 10.1016/s0092-8674(05)80081-9 · doi:10.1016/s0092-8674(05)80081-9 · Paper page

Cited by

See all 131

Metadata

Authors
Yuen, E. Y., Jiang, Q., Chen, P., Feng, J., & Yan, Z.
Affiliations
University at Buffalo, State University of New York (US)
Corresponding author
Yan, Zhen
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2008-06
Volume
283
Issue
25
Pages
17194-17204
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2168545629
Cited by
125
References
53
Citations by year
2026: 4 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 11 · 2014: 5 · 2013: 8 · 2012: 9
FWCI
4.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Alliance for Research on Schizophrenia and Depression
  • National Institutes of Health
  • National Institute of Mental Health (MH 63128, R01MH063128)
  • National Institute of Neurological Disorders and Stroke (NS48911, R01NS048911)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
5-HT2A/C receptor, 5-HT1A receptor, NMDA receptor currents, microtubule depolymerization, beta-arrestin, ERK signaling, NR2B subunit, schizophrenia, depression
MeSH terms
Animals, Cells, Cultured, Electrophysiology, Gene Expression Regulation, Male, Neurons, Serotonin, Receptors, N-Methyl-D-Aspartate, Prefrontal Cortex, Pyramidal Cells, Receptor, Serotonin, 5-HT1A, Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT2C, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of 5-HT2A/C Receptors Counteracts 5-HT1A Regulation of N-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex. https://app.cochat.ai/papers/10.1074/jbc.m801713200
The paper
Yuen, E. Y., Jiang, Q., Chen, P., Feng, J., & Yan, Z. (2008). Activation of 5-HT2A/C Receptors Counteracts 5-HT1A Regulation of N-Methyl-D-aspartate Receptor Channels in Pyramidal Neurons of Prefrontal Cortex. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m801713200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.